Sarah Walbolt/LinkedIn
Aug 20, 2026, 13:15
Sarah Walbolt: Study Findings Challenge Long-Term Anticoagulation
Sarah Walbolt, Program Manager at University of Utah Health, Chief Executive Officer Sanguine Health Holdings Inc, shared a post LinkedIn about a recent article by Sabine Eichinger et al., published in Blood Advances, adding:
”Terminated study due to risk: Findings challenge current treatment paradigms and support individualized decisions regarding anticoagulation duration.
Would love your thoughts!”
Title: Risk of recurrence in patients with provoked venous thromboembolism: a prospective cohort study
Authors: Sabine Eichinger, Lisbeth Eischer, Alexandra Kaider, Georg Heinze, Peter Quehenberger, Paul A. Kyrle
Stay updated on the latest scientific advances with Hemostasis Today.
-
Oct 8, 2026, 17:00Sally Mandour: Platelet Size And Shape Can Reveal The Diagnosis
-
Oct 8, 2026, 16:49Neil Morgan: Advancing Understanding Of Bleeding Disorders Of Unknown Cause
-
Oct 8, 2026, 16:38Beverley Hunt: Advancing Pulmonary Embolism Care Through Collaboration And Learning
-
Oct 8, 2026, 16:19Cedric Hermans: Six Webinars Advancing Haemophilia Care And Beyond
-
Oct 8, 2026, 16:09Luana Banu: Every Donation Connects A Human Chain
-
Oct 8, 2026, 15:51Khaled Musallam: A New Era In Thalassemia Care
-
Oct 8, 2026, 15:40Juan J. Ortiz։ Catheter Directed Therapy In Pulmonary Embolism
-
Oct 8, 2026, 15:34Petros Kountouris: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 8, 2026, 15:14Renzo Mancuso: Human Stem Cell Model Reveals Progenitor Fate in Tissue Macrophages